NASDAQ:DCPH - Deciphera Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $70.50
  • Forecasted Upside: 88.70 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$37.36
▲ +0.52 (1.41%)
1 month | 3 months | 12 months
Get New Deciphera Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DCPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DCPH

Average Price Target: $70.50
▲ +88.70% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Deciphera Pharmaceuticals in the last 3 months. The average price target is $70.50, with a high forecast of $78.00 and a low forecast of $60.00. The average price target represents a 88.70% upside from the last price of $37.36.

Buy

The current consensus among 7 contributing investment analysts is to buy stock in Deciphera Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/25/2019
  • 0 strong buy ratings
  • 13 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/24/2020
  • 0 strong buy ratings
  • 13 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/22/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/20/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/19/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/19/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/18/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/17/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/5/2021HC WainwrightLower Price TargetBuy$80.00 ➝ $75.00High
5/5/2021BarclaysLower Price TargetOverweight$70.00 ➝ $65.00High
5/5/2021Piper SandlerLower Price TargetOverweight$75.00 ➝ $60.00High
3/30/2021Credit Suisse GroupInitiated CoverageOutperform$78.00High
2/10/2021BarclaysLower Price TargetOverweight$85.00 ➝ $70.00Low
2/10/2021SVB LeerinkUpgradeMarket Perform ➝ Outperform$70.00Low
12/2/2020Stifel NicolausInitiated CoverageBuy$75.00Medium
11/12/2020SVB LeerinkBoost Price TargetMarket Perform$58.00 ➝ $70.00Low
9/14/2020SVB LeerinkBoost Price TargetMarket Perform$54.00 ➝ $58.00Medium
9/14/2020JPMorgan Chase & Co.Initiated CoverageNeutralHigh
8/5/2020SVB LeerinkLower Price TargetMarket Perform$55.00 ➝ $54.00Low
6/12/2020GuggenheimReiterated RatingBuy$70.00High
5/18/2020SunTrust BanksBoost Price TargetBuy$82.00 ➝ $91.00Medium
5/18/2020BarclaysReiterated RatingBuy$80.00 ➝ $85.00Medium
5/7/2020Nomura InstinetDowngradeBuy ➝ Neutral$84.00 ➝ $60.00Low
5/6/2020NomuraDowngradeBuy ➝ Neutral$84.00 ➝ $60.00Low
5/6/2020JPMorgan Chase & Co.Lower Price TargetOverweight$50.00 ➝ $49.00High
5/6/2020HC WainwrightBoost Price TargetBuy$60.00 ➝ $80.00High
4/29/2020SunTrust BanksBoost Price TargetBuy$77.00 ➝ $82.00Medium
4/29/2020SVB LeerinkBoost Price TargetHold$50.00 ➝ $55.00Medium
3/4/2020BarclaysInitiated CoverageOverweight$70.00High
1/22/2020Piper SandlerReiterated RatingBuy$75.00Low
1/21/2020Nomura SecuritiesBoost Price TargetBuy$57.00 ➝ $84.00Low
1/15/2020JMP SecuritiesReiterated RatingBuy$70.00Low
1/10/2020SunTrust BanksInitiated CoverageBuy$77.00Low
12/20/2019Piper Jaffray CompaniesBoost Price TargetOverweight$55.00 ➝ $75.00Low
12/20/2019Jefferies Financial GroupBoost Price TargetBuy$53.00 ➝ $77.00Medium
11/5/2019JMP SecuritiesBoost Price TargetOutperform ➝ Market Outperform$45.00 ➝ $54.00Low
10/29/2019SVB LeerinkUpgradeUnderperform ➝ Market Perform$29.00 ➝ $34.00Medium
10/22/2019JMP SecuritiesInitiated CoverageOutperformLow
10/3/2019HC WainwrightInitiated CoverageBuy$60.00High
9/30/2019Piper Jaffray CompaniesSet Price TargetBuy$55.00High
9/30/2019Jefferies Financial GroupInitiated CoverageBuy$47.00High
8/14/2019SunTrust BanksBoost Price TargetPositive ➝ Buy$60.00Low
8/14/2019SVB LeerinkReiterated RatingUnderperform ➝ Positive$20.00 ➝ $29.00High
8/14/2019Cantor FitzgeraldBoost Price TargetOverweight$43.00 ➝ $55.00High
8/14/2019Canaccord GenuityReiterated RatingBuy ➝ Buy$50.00 ➝ $65.00Medium
8/13/2019GuggenheimBoost Price TargetBuy$44.00 ➝ $66.00High
7/18/2019Deutsche Bank AktiengesellschaftInitiated CoverageBuy ➝ Buy$42.00Low
6/3/2019Piper Jaffray CompaniesBoost Price TargetOverweight$50.00 ➝ $55.00High
3/15/2019Canaccord GenuityLower Price TargetBuy ➝ Buy$55.00 ➝ $50.00High
1/1/2019B. RileyDowngradeBuy ➝ NeutralHigh
12/31/2018B. RileyInitiated CoverageNeutral ➝ Buy$27.00 ➝ $34.00High
12/20/2018Cantor FitzgeraldReiterated RatingBuy$53.00Medium
11/16/2018SVB LeerinkLower Price TargetUnderperform$28.00 ➝ $20.00Medium
10/3/2018Cantor FitzgeraldReiterated RatingBuy$53.00Medium
9/24/2018SVB LeerinkInitiated CoverageUnderperform ➝ Underperform$28.00Low
9/17/2018GuggenheimInitiated CoverageBuyHigh
9/6/2018Cantor FitzgeraldInitiated CoverageBuy$53.00High
8/29/2018Raymond JamesInitiated CoverageOutperform ➝ Outperform$47.00Medium
8/22/2018Cantor FitzgeraldInitiated CoverageOverweight$53.00Medium
8/13/2018Canaccord GenuitySet Price TargetBuy$55.00Low
8/7/2018Canaccord GenuityInitiated CoverageBuy$55.00Low
7/5/2018SunTrust BanksInitiated CoverageBuyHigh
6/19/2018JMP SecuritiesBoost Price TargetOutperform$65.00Low
6/19/2018B. RileyDowngradeBuy ➝ Neutral$43.00Medium
6/12/2018Piper Jaffray CompaniesBoost Price TargetOverweight$50.00Low
6/4/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$30.00 ➝ $33.00High
5/9/2018B. RileyLower Price TargetBuy ➝ Buy$52.00 ➝ $43.00High
2/16/2018B. RileyInitiated CoverageBuy ➝ Buy$43.00High
10/23/2017Nomura SecuritiesInitiated CoverageBuy ➝ Buy$57.00N/A
10/23/2017Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$35.00N/A
10/23/2017Nomura InstinetInitiated CoverageBuy$57.00N/A
10/23/2017JMP SecuritiesInitiated CoverageMkt Outperform ➝ Outperform$38.00N/A
10/23/2017JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$30.00N/A
(Data available from 6/18/2016 forward)
Deciphera Pharmaceuticals logo
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing immunokinase inhibitors comprising vimseltinib (DCC-3014) that is in Phase 1b/2 clinical trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase 1b/2 clinical trial to treat metastatic solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, it is developing DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. The company serves in the United States and Europe. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $37.36
Low: $35.91
High: $38.02

50 Day Range

MA: $38.22
Low: $32.73
High: $47.95

52 Week Range

Now: $37.36
Low: $31.77
High: $68.40

Volume

1,001,085 shs

Average Volume

447,809 shs

Market Capitalization

$2.17 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.51

Frequently Asked Questions

What sell-side analysts currently cover shares of Deciphera Pharmaceuticals?

The following Wall Street research analysts have issued reports on Deciphera Pharmaceuticals in the last year: Barclays PLC, Credit Suisse Group AG, HC Wainwright, JPMorgan Chase & Co., Piper Sandler, Stifel Nicolaus, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for DCPH.

What is the current price target for Deciphera Pharmaceuticals?

6 Wall Street analysts have set twelve-month price targets for Deciphera Pharmaceuticals in the last year. Their average twelve-month price target is $70.50, suggesting a possible upside of 88.7%. Credit Suisse Group AG has the highest price target set, predicting DCPH will reach $78.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $60.00 for Deciphera Pharmaceuticals in the next year.
View the latest price targets for DCPH.

What is the current consensus analyst rating for Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals currently has 1 hold rating and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DCPH will outperform the market and that investors should add to their positions of Deciphera Pharmaceuticals.
View the latest ratings for DCPH.

What other companies compete with Deciphera Pharmaceuticals?

How do I contact Deciphera Pharmaceuticals' investor relations team?

Deciphera Pharmaceuticals' physical mailing address is 200 SMITH STREET, Waltham MA, 02451. The company's listed phone number is (781) 209-6400 and its investor relations email address is [email protected] The official website for Deciphera Pharmaceuticals is www.deciphera.com.